Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||APL-1202 + Tislelizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|APL-1202||APL1202|APL 1202||APL-1202 is a methionine aminopeptidase II inhibitor that potentially inhibits tumor angiogenesis and induces apoptosis (European Urology Supplements, Volume 15, Issue 3, e215).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04813107||Phase Ib/II||APL-1202 + Tislelizumab Tislelizumab||A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)||Recruiting||USA||1|